Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of biologic active ingredients.

As a part of this expansion, Lilly will create another 150 jobs for highly skilled workers in Limerick, bringing its total site workforce to 450.

Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients,